Inactivated Rabies Virus-Vectored Immunocontraceptive Vaccine in a Thermo-Responsive Hydrogel Induces High and Persistent Antibodies against Rabies, but Insufficient Antibodies against Gonadotropin-Releasing Hormone for Contraception
Open Access
- 25 July 2019
- Vol. 7 (3), 73
- https://doi.org/10.3390/vaccines7030073
Abstract
Rabies is preventable through vaccination, but the need to mount annual canine vaccination campaigns presents major challenges in rabies control and prevention. The development of a rabies vaccine that ensures lifelong immunity and animal population management in one dose could be extremely advantageous. A nonsurgical alternative to spay/neuter is a high priority for animal welfare, but irreversible infertility in one dose has not been achieved. Towards this goal, we developed a rabies virus-vectored immunocontraceptive vaccine ERA-2GnRH, which protected against rabies virus challenge and induced >80% infertility in mice after three doses in a live, liquid-vaccine formulation (Wu et al., 2014). To improve safety and use, we formulated an inactivated vaccine in a thermo-responsive chitosan hydrogel for one-dose delivery and studied the immune responses in mice. The hydrogel did not cause any injection site reactions, and the killed ERA-2GnRH vaccine induced high and persistent rabies virus neutralizing antibodies (rVNA) in mice. The rVNA in the hydrogel group reached an average of 327.40 IU/mL, more than 200 times higher than the liquid vaccine alone. The Gonadotropin-releasing hormone (GnRH) antibodies were also present and lasted longer in the hydrogel group, but did not prevent fertility in mice, reflecting a possible threshold level of GnRH antibodies for contraception. In conclusion, the hydrogel facilitated a high and long-lasting immunity, and ERA-2GnRH is a promising dual vaccine candidate. Future studies will focus on rabies protection in target species and improving the anti-GnRH response.This publication has 55 references indexed in Scilit:
- Host–rabies virus protein–protein interactions as druggable antiviral targetsProceedings of the National Academy of Sciences of the United States of America, 2013
- Evidence‐based control of canine rabies: a critical review of population density reductionJournal of Animal Ecology, 2012
- Antibody persistence, 32 years after post-exposure prophylaxis with human diploid cell rabies vaccine (HDCV)Vaccine, 2011
- Evaluation of Mass Vaccination Campaign Coverage Against Rabies in Dogs in TunisiaZoonoses and Public Health, 2011
- Development of combined vaccines for rabies and immunocontraceptionVaccine, 2009
- ORIGINAL ARTICLE: The Single‐Shot GnRH Immunocontraceptive Vaccine (GonaCon™) in White‐Tailed Deer: Comparison of Several GnRH PreparationsAmerican Journal of Reproductive Immunology, 2008
- Survival of neutralizing antibody in previously rabies vaccinated subjects: A prospective study showing long lasting immunityVaccine, 2006
- Long-Term Humoral and Cellular Immunity after Vaccination with Cell Culture Rabies Vaccines in ManClinical Immunology and Immunopathology, 1994
- Longevity of rabies antibody titre in recipients of human diploid cell rabies vaccineVaccine, 1992
- RabiesScientific American, 1980